The following is written by Sheldon S. Sones, RPh, FASCP, President, Sheldon S. Sones and Associates. Monoamine oxidase inhibitors (MAO inhibitors or MAOIs) are drugs which, by virtue of their ...

The French Society for Biological Psychiatry and Neuropsychopharmacology has unveiled revised guidelines for the management of depressive disorders with partial and resistant responses to treatment.

Science, founded by Thomas A. Edison in 1880 and published by AAAS, today ranks as the world's largest circulation general science journal. Published 51 times a year, Science is renowned for its ...

Inhibiting human monoamine oxidase (MAO)-B to increase the availability of monoamine neurotransmitters is a clinically approved strategy for treating Parkinson’s disease, yet available inhibitors lack ...

A randomized clinical trial examined patient quality of life in Parkinson disease (PD) when adding different adjuvant therapies to levodopa to help control dyskinesia and a flaring of symptoms during ...

Nicotine & Tobacco Research, Vol. 3, No. 4 (November 2001), pp. 383-390 (8 pages) Previous studies have found that constituents in tobacco inhibit both forms of the enzyme monoamine oxidase (MAO-A and ...

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the neurochemical ...